natgillin/translations-raw huggingface dataset:
Elosulfase alfa is intended to provide the exogenous enzyme N-acetylgalactosamine-6-sulfatase that will be taken up into the lysosomes and increase the catabolism of the GAGs KS and C6S.
Elosulfaza alfa je zamišljena kao egzogeni nadomjestak enzima N- acetilgalaktozamin-6-sulfataze koji će biti transportiran u lizosome i povećati katabolizam GAG-ova, KS-a i C6S.
Elosulfase alfa is produced by a method known as ‘recombinant DNA technology’: it is made by cells into which a gene (DNA) has been introduced, which makes them able to produce the enzyme.
Elosulfaza alfa proizvodi se metodom poznatom pod nazivom „tehnologija rekombinantne DNK”: proizvode ga stanice u koje je umetnut gen (DNK), što omogućuje proizvodnju enzima.
Elotuzumab also attaches to SLAMF7 on the cancer cells, making them more vulnerable to attack by the immune cells.
Elotuzumab se također vezuje za SLAMF7 na stanicama raka što ih čini podložnijima napadu imunosnih stanica.
Elotuzumab also targets SLAMF7 on myeloma cells and facilitates the interaction with natural killer cells to mediate the killing of myeloma cells through antibody-dependent cellular cytotoxicity (ADCC).
Elotuzumab također ciljano djeluje na SLAMF7 na stanicama mijeloma te olakšava interakciju s NK stanicama radi posredovanja u uništavanju stanica mijeloma putem stanične citotoksičnosti ovisne o protutijelima (engl. antibody-dependent cellular cytotoxicity, ADCC).
Elotuzumab exhibits nonlinear pharmacokinetics with clearance of elotuzumab decreasing from
Elotuzumab pokazuje nelinearnu farmakokinetiku kod koje se klirens elotuzumaba smanjuje sa
Elotuzumab is an immunostimulatory humanised, IgG1 monoclonal antibody that specifically targets the SLAMF7 (signaling lymphocyte activation molecule family member 7) protein.
Elotuzumab je imunostimulirajuće humanizirano IgG1 monoklonsko protutijelo koje specifiično ciljano djeluje na protein SLAMF7 (član 7 obitelji signalnih molekula za aktivaciju limfocita [engl. signaling lymphocyte activation molecule family member 7].
Elotuzumab is dosed via intravenous route and therefore is immediately and completely bioavailable.
Elotuzumab se primjenjuje intravenskim putem i stoga je njegova bioraspoloživost trenutačna i potpuna.
Elotuzumab will be given in combination with lenalidomide and breast-feeding should be stopped because of the use of lenalidomide.
Elotuzumab će se primjenjivati u kombinaciji s lenalidomidom, te se dojenje mora prekinuti zbog primjene lenalidomida.
Eltrombopag administration can cause abnormal liver function and severe hepatotoxicity, which might be life-threatening.
Primjena eltrombopaga može poremetiti normalnu funkciju jetre i uzrokovati tešku hepatotoksičnost, koja može biti opasna po život.
Eltrombopag did not affect female fertility, early embryonic development or embryofoetal development in rats at doses up to 20 mg/kg/day (2 times the human clinical exposure in adult or adolescent (12-17 years) ITP patients at 75 mg/day and equivalent to the human clinical exposure in HCV patients at 100 mg/day, based on AUC).
Eltrombopag nije utjecao na plodnost ženki, rani embrionalni razvoj ili embriofetalni razvoj štakora u dozama do 20 mg/kg/dan (2 puta veća od kliničke izloženosti odraslih bolesnika ili adolescenata (u dobi od 12 do 17 godina) s ITP-om pri dozi od 75 mg/dan i ekvivalent kliničke izloženosti bolesnika s HCV-om pri dozi od 100 mg/dan, temeljeno na AUC).
Eltrombopag dose adjustment is permitted during the course of the treatment based on the patient’s platelet count (see section 4.2).
Prilagođavanje doze eltrombopaga dopušteno je tijekom liječenja temeljem broja trombocita svakog pojedinog bolesnika (vidjeti dio 4.2).
Eltrombopag dose, once daily
doza eltrombopaga, jednom dnevno
Eltrombopag dosing requirements must be individualised based on the patient’s platelet counts.
Režim doziranja eltrombopaga mora biti individualiziran i temeljen na broju trombocita svakog pojedinog bolesnika.
Eltrombopag given in combination with peginterferon alfa-2a (180 mcg once weekly for 48 weeks for genotypes 1/4/6; 24 weeks for genotype 2/3) plus ribavirin (800 to 1200 mg daily in 2 divided doses orally)
Eltrombopag dan u kombinaciji s peginterferonom alfa-2a (180 μg jednom tjedno tijekom 48 tjedana za genotip 1/4/6; 24 tjedna za genotip 2/3) uz ribavirin (800 do 1200 mg dnevno u 2 odvojene peroralne doze)
Eltrombopag given in combination with peginterferon alfa-2b (1.5 mcg/kg once weekly for
Eltrombopag dan u kombinaciji s peginterferonom alfa-2b (1,5 μg/kg jednom tjedno tijekom
Eltrombopag interacts with the transmembrane domain of the human TPO-R and initiates signalling cascades similar but not identical to that of endogenous thrombopoietin (TPO), inducing proliferation and differentiation from bone marrow progenitor cells.
Eltrombopag reagira s transmembranskom domenom humanog TPO-R i započinje signalnu kaskadu sličnu, iako ne i identičnu, djelovanju endogenog trombopoetina, potičući proliferaciju i diferencijaciju iz progenitorskih stanica koštane srži.
Eltrombopag is highly bound to human plasma proteins (> 99.9%), predominantly to albumin.
Eltrombopag se izrazito veže za proteine ljudske plazme (> 99,9%), prvenstveno za albumin.
Eltrombopag should not be used in ITP patients with hepatic impairment (Child-Pugh score ≥ 5) unless the expected benefit outweighs the identified risk of portal venous thrombosis (see section 4.4).
Eltrombopag ne smiju uzimati bolesnici s ITP-om s oštećenjem jetre (≥ 5 bodova po Child-Pugh ljestvici) osim ako očekivana dobrobit ne nadmašuje već poznati rizik za trombozu portalne vene (vidjeti dio 4.4).
Eltrombopag should not be used in ITP patients with hepatic impairment (Child-Pugh score ≥ 5) unless the expected benefit outweighs the identified risk of portal venous thrombosis.
Eltrombopag ne treba primjenjivati kod bolesnika s ITP-om i oštećenjem jetre (≥ 5 bodova po Child-Pugh ljestvici), osim ako očekivana dobrobit ne nadmašuje već poznati rizik za nastanak tromboze portalne vene.
Eltrombopag should not be used in patients with hepatic impairment (Child Pugh score ≥ 5) unless the expected benefit outweighs the identified risk of portal venous thrombosis.
Eltrombopag ne treba primjenjivati u bolesnika s oštećenjem jetre (Child-Pugh skor ≥ 5), osim ako očekivana dobrobit ne nadmašuje već poznati rizik za nastanak tromboze portalne vene.
Eltrombopag should not be used outside of clinical trials for the treatment of thrombocytopenia due to MDS or any other cause of thrombocytopenia other than the approved indications.
Eltrombopag se ne bi trebao koristiti izvan kliničkih ispitivanja za liječenje trombocitopenije koja je posljedica MDS-a ili bilo kojeg drugog uzroka trombocitopenije osim za odobrene indikacije.
Eltrombopag should only be administered to such patients after careful consideration of the expected benefits in comparison with the risks.
Eltrombopag se može dati tim bolesnicima tek nakon pažljive procjene odnosa očekivane koristi naspram rizika.
Eltrombopag should only be administered to such patients after careful consideration of the expected benefits in comparison with the risks.
U tih bolesnika eltrombopag treba primjenjivati samo nakon pomnog razmatranja očekivane koristi u odnosu na rizik primjene.
Eltrombopag treatment should be initiated and remain under the supervision of a physician who is experienced in the treatment of haematological diseases or the management of chronic hepatitis C and its complications.
Liječenje eltrombopagom treba započeti i provoditi pod nadzorom liječnika specijalista s iskustvom u liječenju hematoloških bolesti ili s iskustvom u liječenju kroničnog hepatitisa C i njegovih komplikacija.
Eltrombopag was studied in a single-arm, single-centre open-label trial in 43 patients with severe aplastic anaemia with refractory thrombocytopenia following at least one prior immunosuppressive therapy (IST) and who had a platelet count ≤ 30,000/µl.
Eltrombopag se proučavao u otvorenom ispitivanju s jednom skupinom koje se provodilo u jednom centru, u 43 bolesnika s teškom aplastičnom anemijom s refrakternom trombocitopenijom nakon najmanje jedne prethodne imunosupresivne terapije (IST), koji su imali broj trombocita ≤ 30 000/μl.
Eluates should only be taken from a technetium (99mTc)-generator that has been eluted within the past 24 hours (i.e. with less than 24 h in-grow).
Upotrijebiti treba samo ispirke iz generatora tehnecija (99mTc) učinjenih u zadnja 24 sata (tj. s prirastom kraćim od 24 sata).
Eluxadoline has a low potential for drug-drug interactions based on limited in vitro CYP inhibition/induction and given that eluxadoline is not a substrate for CYPs at clinically meaningful concentrations.
Eluksadolin ima niski potencijal za interakciju s drugim lijekovima na temelju ograničene in vitro CYP inhibicije/indukcije i s obzirom da eluksadolin nije supstrat za CYP-ove pri klinički značajnim koncentracijama.
Eluxadoline has not been specifically studied in patients who have renal impairment.
Eluksadolin nije posebno ispitan u bolesnika koji imaju oštećenje funkcije bubrega.
Eluxadoline increases the exposure of the co-administered OATP1B1 substrate; rosuvastatin (see section 5.2) by up to 40% of the total exposure which is usually not considered to be clinically relevant.
Eluksadolin povećava izloženost istodobno primijenjenom supstratu OATP1B1, rosuvastatinu (vidjeti dio 5.2) do 40% od ukupne izloženosti koja se obično ne smatra klinički relevantnom.
Eluxadoline is a locally acting, mixed mu opioid receptor (μOR) agonist and delta opioid receptor (δOR) antagonist.
Eluksadolin je lokalno djelujući, miješani agonist mi-opioidnih receptora (μOR) i antagonist delta- opioidnih receptora (δOR).
Eluxadoline is a substrate of the hepatic uptake transporter OATP1B1.
Eluksadolin je supstrat prijenosnika jetrenog unosa OATP1B1.
Eluxadoline is not an inducer/inhibitor of major CYP enzymes, however, eluxadoline has some potential for the metabolism based inactivation of CYP3A4.
Eluksadolin ne djeluje kao induktor/inhibitor glavnih enzima CYP, međutim, eluksadolin ima određene mogućnosti inaktivacije CYP3A4 koja se temelji na metabolizmu.
Eluxadoline is primarily excreted in the feces, either as unabsorbed active substance or via the biliary system with the kidney playing a minimal role in elimination.
Eluksadolin se prvenstveno izlučuje putem fecesa, bilo kao neapsorbirana djelatna tvar ili putem bilijarnog sustava, pri čemu bubreg ima minimalnu ulogu u eliminaciji.
Eluxadoline may increase the exposure of co-administered medicinal products metabolised by Cytrochrome CYP3A4.
Eluksadolin može povećati izloženost istodobno primijenjenim lijekovima koji se metaboliziraju putem citokroma CYP3A4.
Eluxadoline should not be restarted in patients who developed biliary duct obstruction or sphincter of Oddi spasm while taking eluxadoline (see section 4.3).
Liječenje eluksadolinom se ne smije ponovo započeti u bolesnika kod kojih se javila opstrukcija žučnih kanala ili spazam Oddijevog sfinktera tijekom uzimanja eluksadolina (vidjeti dio 4.3).
Eluxadoline’s systemic exposure following oral administration is low and is consistent with its local action in the GI tract.
Sistemsko izlaganje eluksadolinu nakon peroralne primjene je nisko i u skladu s lokalnim djelovanjem u GI traktu.
elvitegravir
Elvitegravir (150 mg
Elvitegravir (125 mg once daily)
Elvitegravir (125 mg jedanput na
Elvitegravir (150 mg once daily)
Elvitegravir (150 mg jedanput na
Elvitegravir (150 mg once daily)
Fluvastatin
Elvitegravir (150 mg once daily)
Kobicistat (150 mg jedanput na dan)
Elvitegravir (150 mg once daily) Cobicistat (150 mg once daily)
Elvitegravir (150 mg jedanput na
Elvitegravir (150 mg once daily) Cobicistat (150 mg once daily)1
Elvitegravir (150 mg jedanput na
Elvitegravir (150 mg once daily)/ Cobicistat (150 mg once daily)
10 mg)/elvitegravir (150 mg jedanput na dan)/kobicistat (150 mg jedanput na dan)
Elvitegravir (150 mg once daily)/Cobicistat (150 mg once daily)1
Elvitegravir (150 mg jedanput na dan)/kobicistat (150 mg jedanput na dan)1
Elvitegravir (200 mg once daily)
Elvitegravir (200 mg jedanput na
Elvitegravir (300 mg once daily)
Elvitegravir (300 mg jedanput na dan)
Elvitegravir (50 mg once daily)
Elvitegravir (50 mg jedanput na
Elvitegravir (85 mg once daily)
Elvitegravir (85 mg jedanput na
Elvitegravir (antacid suspension
Elvitegravir (antacidna
Elvitegravir (antacid suspension after ± 2 hours): AUC: ↔
Elvitegravir (antacidna suspenzija nakon ± 2 sata): AUC: ↔
Elvitegravir (simultaneous
Elvitegravir (istodobna primjena
elvitegravir administration):
primjene elvitegravira):
Elvitegravir AUC24: ↔ 1.07 (0.96-1.18)
Elvitegravir AUC24: ↔ 1,07 (0,96-1,18)
elvitegravir Cmax ↔ darunavir AUC ↔
elvitegravir Cmax ↔
Elvitegravir did not show any carcinogenic potential in long-term oral carcinogenicity studies in mice and rats.
Dugotrajna ispitivanja kancerogenosti elvitegravira nisu pokazala kancerogenosti potencijal u miševa i štakora.
Elvitegravir displayed antiviral activity in cell culture against HIV-1 clades A, B, C, D, E, F, G, and O (EC50 values ranged from 0.1 to 1.3 nM) and activity against HIV-2 (EC50 of 0.53 nM).
Elvitegravir je pokazao antivirusno djelovanje u staničnoj kulturi na HIV-1 podtipove A, B, C, D, E, F, G i O (vrijednosti EC50 u rasponu od 0,1 do 1,3 nM) i djelovanje na HIV-2 (EC50 od 0,53 nM).
Elvitegravir displayed antiviral activity in cell culture against HIV-1 clades A, B, C, D, E, F, G, and O (EC50 values ranged from 0.1 to 1.3 nM) and activity against HIV-2 (EC50 of 0.53 nM).
Elvitegravir je pokazao antivirusnu aktivnost u staničnoj kulturi na HIV-1 podtipove A, B, C, D, E, F, G i O (vrijednosti EC50 u rasponu od 0,1 do 1,3 nM) i aktivnost na HIV-2 (EC50 od 0,53 nM).
Elvitegravir does not inhibit human topoisomerases I or II.
Elvitegravir ne inhibira humane topoizomeraze I ili II.
elvitegravir in combination with cobicistat is not recommended (see section 4.4).
Istodobna primjena Viramunea s elvitegravirom u kombinaciji s kobicistatom se ne preporučuje (vidjeti dio 4.4).
Elvitegravir is a type of antiviral agent called an ‘integrase inhibitor’.
Elvitegravir je antivirusni lijek poznat kao inhibitor integraze.
Elvitegravir plasma concentrations
Koncentracije elvitegravira u plazmi
Elvitegravir plasma concentrations are lower with antacids due to local complexation in the gastrointestinal tract and not to changes in gastric pH.
Koncentracije elvitegravira u plazmi niže su s antacidima zbog lokalne kompleksacije u gastrointestinalnom traktu, a ne zbog promjena želučanih pH- vrijednosti.
Elvitegravir plasma exposures are non-linear and less than dose-proportional, likely due to solubility- limited absorption.
Izloženosti elvitegraviru u plazmi su nelinearne i manje od onih proporcionalnih dozi, vjerojatno zbog apsorpcije ograničene topljivošću.
Elvitegravir undergoes oxidative metabolism by CYP3A (major route), and glucuronidation by UGT1A1/3 enzymes (minor route).
Elvitegravir prolazi kroz oksidativni metabolizam putem CYP3A (glavni put) i kroz glukuronidaciju putem UGT1A1/3 enzima (sporedni put).
Elvitegravir was negative in an in vitro bacterial mutagenicity test (Ames test) and negative in an in vivo rat micronucleus assay at doses up to 2,000 mg/kg.
Elvitegravir je bio negativan u in vitro pretrazi bakterijske mutagenosti (Amesov test) i negativan u in vivo analizi mikronukleusa štakora u dozama od 2000 mg/kg.
elvitegravir with oral
elvitegravira s oralnim
elvitegravir, an antiretroviral medicine known as an integrase inhibitor
elvitegravir, antiretrovirusni lijek poznat kao inhibitor integraze
elvitegravir, an antiretroviral medicine known as an integrase inhibitor cobicistat, a booster (pharmacokinetic enhancer) of the effects of elvitegravir
elvitegravir, antiretrovirusni lijek poznat kao inhibitor integraze kobicistat, pojačivač (farmakokinetički pojačivač) učinaka elvitegravira
Elvitegravir-resistant viruses show cross-resistance to the integrase strand transfer inhibitor raltegravir in most cases (see section 5.1).
Virusi rezistentni na elvitegravir u većini slučaja pokazuju križnu rezistenciju na raltegravir, inhibitor prijenosa lanca integraze (vidjeti dio 5.1).
elvitegravir.
elvitegravira u plazmi.
elvitegravir.
elvitegravirom.
Elvitegravir/
Elvitegravir/kobicistat
Elvitegravir/ cobicistat
Elvitegravir/kobicistat
Elvitegravir/ cobicistat/ emtricitabine/ tenofovir alafenamide fumarate (150/ 150/ 200/ 10 mg once daily)/ sofosbuvir/ velpatasvir (400/ 100 mg once daily)c, d
Elvitegravir/kobicistat/emtricitabin/ tenofoviralafenamidfumarat (150/150/200/10 mgjedanput na dan)/sofosbuvir/velpatasvir (400/100 mg jedanput na dan)c, d
Elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil fumarate (150/ 150/ 200/ 300 mg once daily)/ sofosbuvir/ velpatasvir (400/ 100 mg once daily)c, d
Elvitegravir/kobicistat/emtricitabin/ tenofovirdizoproksilfumarat (150/150/200/300 mg jedanput na dan)/sofosbuvir/velpatasvir (400/100 mg jedanput na dan)c, d
Elvitegravir/Cobicistat
Buprenorfin/nalokson/ elvitegravir/kobicistat
elvitegravir/cobicistat have not been
elvitegravirom/kobicistatom nisu
Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (fixed-dose combination)
Elvitegravir/kobicistat/emtricitabin/tenofovir dizoproksilfumarat (kombinacija fiksnih doza)
elvitegravir/ritonavir
elvitegravirom/ritonavirom
Elvitegravir: AUC: ↔* Cmax: ↔*
Elvitegravir: AUC: ↔* Cmax: ↔* Cmin: ↔
EMA/140299/2015 Page 2/2
EMA/140299/2015 Stranica 2/2
EMA/14965/2015 Page 2/2
EMA/14965/2015 Stranica 2/2
EMA/159853/2016 Page 2/2
EMA/159853/2016 Stranica 2/2
EMA/173510/2016 Page 2/2
EMA/173510/2016 Stranica 2/2
EMA/243539/2016 Page 2/2
EMA/243539/2016 Stranica 2/2
EMA/277939/2015 Page 2/2
EMA/277939/2015 Stranica 2/2
EMA/281859/2016 Page 2/2
EMA/75811/2016 Stranica 2/2
EMA/284074/2016 Page 2/2
EMA/284074/2016 Stranica 2/2
EMA/295851/2014 Page 2/2
EMA/334757/2014 Stranica 2/2
EMA/300817/2013 Page 2/2
EMA/300817/2013 Stranica 2/2
EMA/310857/2016 Page 2/2
EMA/310857/2016 Stranica 2/2
EMA/312188/2015 Page 2/2
EMA/515402/2015 Stranica 2/2
EMA/312727/2016 Page 2/2
EMA/478233/2016 Stranica 2/2
EMA/313571/2016 Page 2/2
EMA/416440/2016 Stranica 2/2
EMA/335824/2014 Page 2/2
EMA/334757/2014 Stranica 2/2
EMA/351750/2015 Page 2/2
EMA/351750/2015 Stranica 2/2
EMA/357446/2015 Page 2/2
EMA/357446/2015 Stranica 2/2
EMA/374036/2015 Page 2/2
EMA/516489/2015 Stranica 2/2
EMA/388793/2009 Page 2/2
EMA/433369/2014 Stranica 2/2
EMA/403410/2014 Page 2/2
EMA/547809/2014 Stranica 2/2
EMA/403781/2014 Page 2/2
EMA/547812/2014 Stranica 2/2
EMA/403892/2016 Page 2/2
EMA/403892/2016 Stranica 2/2
EMA/404586/2013 Page 2/2
EMA/404586/2013 Stranica 2/2
EMA/419868/2016 Page 2/2
EMA/419868/2016 Stranica 2/2
EMA/422021/2014 Page 2/2
EMA/422021/2014 Stranica 2/2
EMA/424866/2015 Page 2/2
EMA/424871/2015 Stranica 2/2
EMA/429103/2013 Page 2/2
EMA/429103/2013 Stranica 2/2
EMA/438073/2015 Page 2/2
EMA/438050/2015 Stranica 2/2
EMA/439020/2015 Page 2/2
EMA/439020/2015 Stranica 2/2
EMA/450050/2016 Page 2/2
EMA/450050/2016x Stranica 2/2
EMA/458697/2016 Page 2/2
EMA/458697/2016 Stranica 2/2
EMA/463551/2015 Page 2/2
EMA/383424/2015 Stranica 2/2
EMA/464656/2009 Page 2/2
EMA/464656/2009 Stranica 2/2
EMA/470505/2014 Page 2/2
EMA/470494/2014 Page 2/2
EMA/477286/2015 Page 2/2
EMA/477286/2015 Stranica 2/2
EMA/482355/2014 Page 2/2
EMA/482355/2014 Stranica 2/2
EMA/511707/2015 Page 2/2
EMA/14880/2015 Stranica 2/2
EMA/514077/2013 Page 2/2
EMA/505702/2013 Stranica 2/2
EMA/524629/2014 Page 2/2
EMA/427218/2014 Stranica 2/2
EMA/55700/2016 Page 2/2
Stranica 2/2
EMA/590871/2015 Page 2/2
EMA/743573/2013 Stranica 2/2
EMA/593111/2013 Page 2/2
EMA/593111/2013 Stranica 2/2
EMA/658100/2014 Page 2/2
EMA/658100/2014 Stranica 2/2
EMA/65956/2015 Page 2/2
EMA/65962/2015 Stranica 2/2
EMA/698698/2013 Page 2/2
EMA/698698/2013 Stranica 2/2
EMA/712450/2015 Page 2/2
EMA/712450/2015 Stranica 2/2
EMA/727056/2013 Page 2/2
EMA/727056/2013 Stranica 2/2
EMA/729961/2014 Page 2/2
EMA/746690/2014 Stranica 2/2
EMA/776490/2015 Page 2/2
EMA/634867/2015 Stranica 2/2
EMA/783550/2013 Page 2/2
EMA/783550/2013 Stranica 2/2
EMA/805509/2014 Page 2/2
EMA/805509/2014 Stranica 2/2
EMA/807134/2013 Page 2/2
EMA/807134/2013 Stranica 2/2
EMA/89273/2016 Page 2/2
EMEA/H/C/003938 Stranica 2/2
EMA/CHMP/328573/2014 Page 2/2
EMA/265372/2014 Stranica 2/2
EMA/CHMP/371429/2015 Page 2/2
EMA/429824/2013 Stranica 2/2
EMA/CVMP/064/97 Page 2/2
EMEA/CVMP/064/97 Stranica 2/2
EMA/CVMP/214641/2008 Page 2/2
Stranica 2/2
EMADINE 0.5 mg/ml Eye Drops, solution
EMADINE 0,5mg/ml kapi za oko, otopina
EMADINE 0.5 mg/ml Eye Drops, solution, single-dose container.
EMADINE 0,5 mg/ml kapi za oko, otopina, jednodozni spremnik.
EMADINE 0.5 mg/ml, Eye Drops, solution
EMADINE 0,5 mg/ml, kapi za oko, otopina
EMADINE has no or negligible influence on the ability to drive and use machines, however as with any ocular medication, if transient blurred vision or other visual disturbance occurs at instillation, the patient should wait until the vision clears before driving or using machinery.
EMADINE nema ili ima zanemariv utjecaj na sposobnost upravljanja vozilima i rada sa strojevima, ipak, kao i pri primjeni bilo kojeg oftalmičkog lijeka, ako se se kod ukapavanja pojavi prolazno zamućenje vida ili drugi vidni poremećaji, bolesnik treba pričekati da se vid razbistri prije nego krene upravljati vozilom ili raditi na stroju.
EMADINE has not been studied in elderly patients older than 65 years, and therefore its use is not recommended in this population.
EMADINE nije ispitan u osoba starijih od 65 godina te se stoga njegova primjena toj populaciji ne preporučuje.
EMADINE is a liquid (a solution) supplied in a pack containing a 5 ml or 10 ml plastic (DROP-TAINER) bottle with a screw cap.
EMADINE je tekućina (otopina) dostupna u pakovanju koje sadržava plastičnu bočicu (DROP- TAINER) od 5 ml ili 10 ml, sa zatvaračem s navojem.
EMADINE is a liquid (a solution) supplied in single-dose plastic containers which contain 0.35 ml.
EMADINE je tekućina (otopina) dostupna u plastičnim jednodoznim spremnicima od 0,35 ml.
EMADINE is not recommended for use in patients over 65 years of age, as it has not been studied in clinical trials in this age group.
EMADINE se ne preporučuje osobama starijim od 65 godina jer u toj dobnoj skupini lijek nije ispitan u kliničkim ispitivanjima.
EMADINE is not recommended for use in patients with kidney or liver problems.
EMADINE se ne preporučuje osobama koje imaju poteškoće s bubrezima ili jetrom.
Email: dunavet-bp@dunavet.hu
Email:dunavet-bp@dunavet.hu
Email: info@chiesi.com
Elektronička pošta: info@chiesi.com
Email: infoixiaro@valneva.com
Austrija ail: infoixiaro@valneva.com
Email: medical.information@themedco.com
E-mail: medical.information@themedco.com
Email: office@santhera.com
E-pošta office@santhera.com
Email: PatientSafetyFrance@indivior.com
E-mail: PatientSafetyFrance@indivior.com
Email: PatientSafetyRoW@indivior.com
E-mail: PatientSafetyRoW@indivior.com
Embolic and thrombotic events including the increased risk of vessel occlusion in patients at risk of thrombosis
Pojava embolija i tromboza, uključujući povećani rizik od okluzije krvnih žila u bolesnika koji imaju povećan rizik od razvoja tromboze
Embolism (thrombotic embolisation)
Embolija (trombotska embolija)
embolism and deep
tahikardija/fibrilacij
Embolism in the lung
Plućna embolija
Embolism pulmonary, oedema, oedema peripheral
plućna embolija, edem, periferni edem
embolism,
gastrointestinalni ulkusa
embolism,
pneumotoraks,
Embryo-fetal development
Embriofetalni razvoj
Embryo-foetal development studies were conducted with abatacept in mice, rats, and rabbits at doses up to 20 to 30 times a human 10 mg/kg dose and no undesirable effects were observed in the offspring.
Istraživanja embrio- fetalnog razvoja provedena su s abataceptom na miševima, štakorima i kunićima pri dozama do 20-30 puta većima od doze za ljude od 10 mg/kg te nisu opaženi neželjeni učinci na mladunčad.
Embryo-foetal developmental toxicity studies conducted in rats and rabbits revealed no compound- induced malformations or developmental variations when administered during the period of organogenesis.
Ispitivanja razvojne toksičnosti za embrio i fetus provedene na štakorima i zečevima nisu otkrile malformacije uzrokovane lijekom ili varijacije u razvoju prilikom primjene lijeka u razdoblju organogeneze.